Omrix Biopharmaceuticals Revenue and Competitors

Omrix Biopharmaceuticals specializes in the development and manufacture of life-saving products based on human plasma. As a Johnson&Johnson company, we care for the world and are committed to helping people with our innovative solutions. Omrix’s products are based on a unique patented technology and are sold throughout the world. Using advanced biotechnological and human-plasma-based products, our solutions help control bleeding during surgery and people with immune deficiencies. Founded in 1995 by Mr. Robert Taub, Omrix went public on the US Stock Exchange in 2006 under the name OMRI. Two years later, Omrix was acquired by American pharmaceutical giant Johnson & Johnson, one of the world’s largest healthcare companies employing roughly 118,000 people around the world. Today, Omrix reports through ETHICON, Medical Device & Diagnostics unit at Johnson&Johnson. With over 500 employees in 2 main locations in Israel, Omrix’s employees are at the center of the company’s ‘we care’ credo. We provide more than just a workplace; we offer a home where people find they can leave a mark in the medical world of tomorrow. Our success is the success of our employees and vice versa, and thus are always working in synch to develop and deliver products that improve the quality of life of millions of people. We are always looking for talent to join our winning and caring team. Visit Omrix’s career page at: http://www.jnjcareers.co.il/jjcareers-media-author-omrix +972-73-2588501